Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mequitazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mequitazine SCHEMBL29376901 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2ADRA2ACHRM1ADRA2B | |
| Mequitazine SCHEMBL604639 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2ADRA2ACHRM1ADRA2B | |
| Mequitazine SCHEMBL18207 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2ADRA2ACHRM1ADRA2B | |
| Mequitazine SCHEMBL29382350 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2ADRA2ACHRM1ADRA2B | |
| Mequitazine SCHEMBL18208 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2ADRA2ACHRM1ADRA2B | |
| Mequitazine SCHEMBL29379090 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2ADRA2ACHRM1ADRA2B | |
| Mequitazine SCHEMBL11973309 | 0.99 | CYP2D6 (0.97) | CYP2D6CHRM2ADRA2ACHRM1ADRA2B | |
| Mequitazine SCHEMBL28086297 | 0.89 | CYP2D6 (0.79) | CYP2D6CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL23954312 | 0.86 | MAPT (0.74) | CYP2D6CHRM2ADRA2ACHRM1ADRA2B | |
| Oxomemazine SCHEMBL28086314 | 0.77 | CYP2D6 (0.60) | CYP2D6CHRM2ADRA2ACHRM1ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227235-B1 | MEQUITAZINE FOR TREATING OR PREVENTING OBSTRUCTIVE BRONCHOPNEUMOPATY INVOLVING HISTAMINE H4 RECEPTORS | PF MEDICAMENT (FR) | 2014-11-12 | — | — | EP | claimed |
| EP-2255811-A1 | Mequitazine for treating or preventing pathologies involving histamine H4 receptors | PIERRE FABRE MEDICAMENT (FR) | 2010-12-01 | — | — | EP | claimed |
| US-20100273752-A1 | MEQUITAZINE FOR TREATING OR PREVENTING PATHOLOGIES INVOLVING HISTAMINE H4 RECEPTORS | PIERRE FABRE MEDICAMENT (FR) | 2010-10-28 | — | — | US | claimed |
| EP-2227235-A1 | MEQUITAZINE FOR TREATING OR PREVENTING PATHOLOGIES INVOLVING HISTAMINE H4 RECEPTORS | Pierre Fabre Médicament (FR) | 2010-09-15 | — | — | EP | claimed |
| WO-2009071625-A1 | MEQUITAZINE FOR TREATING OR PREVENTING PATHOLOGIES INVOLVING HISTAMINE H4 RECEPTORS | PIERRE FABRE MEDICAMENT (FR) | 2009-06-11 | — | — | WO | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| WO-2008138968-A4 | DOSAGE FORM COMPRISING 10-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLMETHYL]-10H-PHENOTHIAZINE, PROVIDED IN A FORM SUITABLE FOR ORAL ADMINISTRATION OF A DAILY DOSE OF 1 MG TO 3 MG | PF MEDICAMENT (FR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008138968-A4 | DOSAGE FORM COMPRISING 10-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLMETHYL]-10H-PHENOTHIAZINE, PROVIDED IN A FORM SUITABLE FOR ORAL ADMINISTRATION OF A DAILY DOSE OF 1 MG TO 3 MG | PF MEDICAMENT (FR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009071625-A1 | MEQUITAZINE FOR TREATING OR PREVENTING PATHOLOGIES INVOLVING HISTAMINE H4 RECEPTORS | PIERRE FABRE MEDICAMENT (FR) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071625-A1 | MEQUITAZINE FOR TREATING OR PREVENTING PATHOLOGIES INVOLVING HISTAMINE H4 RECEPTORS | PIERRE FABRE MEDICAMENT (FR) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008138968-A3 | DOSAGE FORM COMPRISING 10-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLMETHYL]-10H-PHENOTHIAZINE, PROVIDED IN A FORM SUITABLE FOR ORAL ADMINISTRATION OF A DAILY DOSE OF 1 MG TO 3 MG | PF MEDICAMENT (FR) | 2009-05-22 | — | — | WO | disclosed |
| WO-2008138968-A3 | DOSAGE FORM COMPRISING 10-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLMETHYL]-10H-PHENOTHIAZINE, PROVIDED IN A FORM SUITABLE FOR ORAL ADMINISTRATION OF A DAILY DOSE OF 1 MG TO 3 MG | PF MEDICAMENT (FR) | 2009-05-22 | — | — | WO | disclosed |
| WO-2008138968-A2 | DOSAGE FORM COMPRISING 10-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLMETHYL]-10H-PHENOTHIAZINE, PROVIDED IN A FORM SUITABLE FOR ORAL ADMINISTRATION OF A DAILY DOSE OF 1 MG TO 3 MG | PIERRE FABRE MEDICAMENT (FR) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138968-A2 | DOSAGE FORM COMPRISING 10-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLMETHYL]-10H-PHENOTHIAZINE, PROVIDED IN A FORM SUITABLE FOR ORAL ADMINISTRATION OF A DAILY DOSE OF 1 MG TO 3 MG | PIERRE FABRE MEDICAMENT (FR) | 2008-11-20 | — | — | WO | disclosed |